Patents Assigned to ApopLogic Pharmaceuticals, Inc.
  • Use of tumor Fas expression to determine response to anti-cancer therapy
    Patent number: 10352936
    Abstract: The invention provides methods for using expression levels of Fas to select individuals or subpopulation of individuals who can benefit from an anti-cancer therapy and for assessing whether an individual suspected of having or developing cancerous tumors will beneficially respond to an anticancer therapy. The invention additionally provides methods of treatment for individuals selected as likely to benefit from anti-cancer therapy based on Fas expression levels.
    Type: Grant
    Filed: April 13, 2012
    Date of Patent: July 16, 2019
    Assignee: ApopLogic Pharmaceuticals, Inc.
    Inventors: Jaime Modiano, Donald Bellgrau, Richard C. Duke